Tag: annual meeting

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24.

TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (“Dundee” or the “Corporation”) is pleased to announce the voting results from its Annual Meeting of Shareholders (the “Meeting”) which was held earlier today. Shareholders voted in favour of all items of business before the Meeting, as follows:

CALGARY, June 19, 2025 (GLOBE NEWSWIRE) -- Condor Energies Inc. (TSX: CDR), a Canadian based energy company, is pleased to announce that the following five director nominees were elected at the Annual Meeting of Shareholders held on June 19, 2025:

CALGARY, Alberta, June 18, 2025 (GLOBE NEWSWIRE) -- Questerre Energy Corporation (“Questerre” or the “Company”) (TSX,OSE:QEC) announced today that, at its annual meeting of shareholders held on June 18, 2025 (the “Meeting”), all matters presented for approval at the Meeting were approved.

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (Cboe Canada: MLC) (“Mount Logan,” “our,” “we,” or the “Company”) announced that at the annual meeting of shareholders held on June 18, 2025 (the “Meeting”), each of the six nominees listed in the management information circular dated May 13, 2025 (the “Circular”) were elected as directors of the Company. A total of 31,979,130 votes or 55.78% of Mount Logan’s issued and outstanding common shares were voted in connection with the Meeting. The detailed results of the vote for each of the six elected directors are set out below.

FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a one-for-thirty reverse stock split (the “Reverse Stock Split”) of the company’s common stock, par value $0.00001, which will become effective at 12:01 a.m. Eastern Time on Tuesday, June 24, 2025. The company’s common stock will continue to trade under its current trading symbol, CLRB, on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis when the market opens on Tuesday, June 24, 2025, with the new CUSIP number 15117F880.

Amends Offer to $1.45 per Share Due to Reduction in Net Asset Value (“NAV”) From Two Recent Asset Sales

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of solid tumors and multiple myeloma, today announced key leadership appointments. Alessandra Cesano, MD, PhD, who has served as Consulting Chief Medical Officer since April 2023, will join the company’s Board of Directors. Florian D. Vogl, MD, PhD, has been appointed as Chief Medical Officer (CMO), succeeding Alessandra Cesano on the executive team.